



Funded by the  
European Union



# NEXUS Consortium Agreement



cnrs

Dr Fairouz Malek, project Coordinator  
Research scientist at CNRS

Nexus Kick-off meeting  
January 22<sup>nd</sup>, 2026



Funded by the  
European Union



# Consortium Agreement (CA) Purpose

The purpose of this Consortium Agreement is to specify with respect to the Project the relationship among the Parties, in particular concerning the organisation of the work between the Parties, the management of the Project and the rights and obligations of the Parties concerning inter alia liability, Access Rights and dispute resolution.

# Consortium Agreement ToC

- 1 Definitions
- 2 Purpose
- 3 Entry into force, duration and termination
- 4 Responsibilities of Parties
- 5 Liability towards each other
- 6 Governance structure
- 7 Financial provisions
- 8 Results
- 9 Access Rights
- 10 Non-disclosure of information
- 11 Miscellaneous
- 12 Signatures

- **Attachment 1:** Consortium Budget
- **Attachment 2:** Identified entities under the same control according to Section 9.5
- **Attachment 3:** Accession document
- **Attachment 4:** [Secondment Agreement](#)
- **Attachment 5:** Background included
- **Attachment 6:** List of third parties for simplified transfer according to Section 8.3.2.
- **Attachment 7:** NDA for External Advisory Board agreed under Section 6

# Entry into force, duration and termination (CA art. 3)

## Entry into force

- An entity becomes a Party to this Consortium Agreement upon signature of this Consortium Agreement by a duly authorised representative.
- This Consortium Agreement shall have effect from the Effective Date identified at the beginning of this Consortium Agreement.
- An entity becomes a new Party to the Consortium Agreement upon signature of the accession document (Attachment 3) by the new Party and the Coordinator. Such accession shall have effect from the date identified in the accession document.

## Duration and termination

- This Consortium Agreement shall continue in full force and effect until complete fulfilment of all obligations undertaken by the Parties under the Grant Agreement and under this Consortium Agreement.
- However, this Consortium Agreement or the participation of one or more Parties to it may be terminated in accordance with the terms of this Consortium Agreement.
- If an Associated Partner's participation in the Project is terminated, its participation in this Consortium Agreement may be terminated subject to the provisions surviving the expiration or termination under this Consortium Agreement (Section 4.2 and Section 3.3).

## Survival of rights and obligations

Termination shall not affect any rights or obligations of a Party leaving the Project incurred prior to the date of termination, unless otherwise agreed between the Management Board and the leaving Party. This includes the obligation to provide all necessary input, deliverables and documents for the period of its participation.



Funded by the  
European Union



# Governance (CA art. 6)

## ☐ Management Board

- Decision-making body
- Deliberation and decisions on topics such as scientific implementation, finances, intellectual property, evolution of the consortium
- Appointment of the SEAB members
- Composition: one representative of each party

## ☐ Executive Board

- Supervisory body for monitoring the execution of the project
- Preparation of the Executive board meeting
- Support in preparing meetings, deliverables, press releases and joint publications of the consortium
- Composition: Coordinator and work package leaders

## ☐ Work Package Leaders

- Composition: Leaders of each work package
- Ensuring the performance of the work packages through regular monitoring
- Delivering feedbacks and progress reports
- Informing the Coordinator of any delay

## ☐ Scientific and Ethics Advisory Board (SEAB)


- Consultative body on scientific and ethical issues
- Composition: representatives of the partners and external experts



Funded by the  
European Union



# Payments (GA art. 22)



1. **Pre-financing (PF)** of 65% of the maximum grant amount - MIM ~ 5% (notified 12/01/2026)

**46 2924 €** (501 501,00 € - 38 577,00 €)

→ Pre-financing will be paid to the Coordinator who will transfer the funds to the Beneficiaries according to the Consortium Agreement

2. **Interim payment** at the end of RP1 (**M24**)

→ Total amount of pre-financing and **interim payment shall not exceed 90%** of the maximum grant amount

3. **Final payment** at the end of RP2 (**M48**)

→ Deadline for making interim and **final payments > 90 days from receiving periodic report**

→ **MIM will be refund**



# Financial provisions (CA art. 7)

<b>Contribution/PM</b>	<b>5 010 €</b>
Top-up allowance	2 710 €
Research training & networking contribution	1 300 €
Management and indirect contribution	1 000 €

## Allocation of institutional costs

- ☐ Collective use of the institutional contributions for
  - The organisation of summer/winter schools
  - The organisation of the project workshop
  - Long-distance secondments of non-eligible partners (SNOLAB, UoA and UoM)
  - Travel and stay expenses of non-eligible partners (LSC, SNOLAB, SURF, UKRI, UoA, UoM)
  - European project manager to support the consortium with the management, organisation of activities and communication
- ☐ The participation of each partner to the 'common pot' will be retained by the Coordinator
- ☐ Payment of the amounts due to the partners according to the planned allocation will be made upon justification of the task performed and actual incurred costs



Funded by the  
European Union



# Financial provisions (CA art. 7)

	Partner	Person-month	Budget before compensation	Planned top-up allowance	Planned institutional contributions	Deducted amount (28,7%)	Compensation for organisational & logistics costs						Budget after compensation	Total available for research, networking, training and management
							Project manager	Kick-off meeting	Project WK	Summer schools	Long-distance secondments (NETC)	Contribution for travels costs (NETC)		
Beneficiaries	CNRS	42	210420	113820	96600	27722,73	43450	5000					231147,27	68877,27
	INFN	70	350700	189700	161000	46204,55			5000				309495,45	114795,45
	SKAO	2	10020	5420	4600	1320,13							8699,87	3279,87
Associated Partners	LSC	0	0	0	0	0						1600	1600,00	0
	SNOLAB	3	0	0	0	0					1500	3000	4500,00	0
	SURF	0	0	0	0	0				10000		3000	13000,00	10000
	SU	22	110220	59620	50600	14521,43							95698,57	36078,57
	UoA	9	0	0	0	0					4500	3000	7500,00	0
	UKRI	0	0	0	0	0						1600	1600,00	0
	UoM	4	0	0	0	0					2000	3000	5000,00	0
	UNISA	5	25050	13550	11500	3300,32							21749,68	8199,68
	UWC	11	55110	29810	25300	7260,71							47849,29	18039,29
	WITS	2	10020	5420	4600	1320,13							8699,87	3279,87
									5000	10000				
Total			771540	417340	354200	101650	43450	5000	10000	20000	8000	15200	771540	252550





Funded by the  
European Union



# Access Rights for Parties entering or leaving the consortium (CA art. 9.7)

## New Parties entering the consortium

As regards Results developed before the accession of the new Party, the new Party will be granted Access Rights on the conditions applying for Access Rights to Background.

## Parties leaving the consortium: Access Rights granted to a leaving Party

### **Defaulting Party**

Access Rights granted to a Defaulting Party and such Party's right to request Access Rights shall cease immediately upon receipt by the Defaulting Party of the formal notice of the decision of the Management Board to terminate its participation in the consortium.

### **Non-defaulting Party**

A non-defaulting Party leaving voluntarily and with the other Parties' consent shall have Access Rights to the Results developed until the date of the termination of its participation.

It may request Access Rights within the period of time specified in Section 9.4.3.

### **Access Rights to be granted by any leaving Party**

Any Party leaving the Project shall continue to grant Access Rights pursuant to the Grant Agreement and this Consortium Agreement as if it had remained a Party for the whole duration of the Project.





# Questions - Comments